TrialHaematologica2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.

Andrew H Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.